Rapid transition to home omalizumab treatment for chronic spontaneous urticaria during the COVID-19 pandemic: A patient perspective
Open Access
- 21 September 2021
- journal article
- research article
- Published by Elsevier BV in World Allergy Organization Journal
- Vol. 14 (10), 100587
- https://doi.org/10.1016/j.waojou.2021.100587
Abstract
No abstract availableKeywords
Funding Information
- Science Foundation Ireland (20/SPP/3685)
This publication has 14 references indexed in Scilit:
- Angioedema and prescribing of omalizumab for chronic urticaria in countries with limited financial resourcesWorld Allergy Organization Journal, 2019
- Multicentre experience of home omalizumab treatment for chronic spontaneous urticariaEuropean Journal of Hospital Pharmacy, 2019
- The EAACI/GA²LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticariaAllergy, 2018
- Home self-administration of omalizumab for chronic spontaneous urticariaBritish Journal of Dermatology, 2016
- Association among stress, hypocortisolism, systemic inflammation, and disease severity in chronic urticariaAnnals of Allergy, Asthma & Immunology, 2016
- Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapyJournal of Allergy and Clinical Immunology, 2013
- Omalizumab for the Treatment of Chronic Idiopathic or Spontaneous UrticariaThe New England Journal of Medicine, 2013
- Self-administration of subcutaneous depot medroxyprogesterone acetate for contraception: feasibility and acceptabilityContraception, 2012
- Patient preferences and satisfaction in the treatment of rheumatoid arthritis with biologic therapyPatient Preference and Adherence, 2009
- Replacement IgG therapy and self-therapy at home improve the health-related quality of life in patients with primary antibody deficienciesCurrent Opinion in Allergy and Clinical Immunology, 2006